research article gene expression profile analysis in...

6
Research Article Gene Expression Profile Analysis in Epilepsy by Using the Partial Least Squares Method Dong Wang, Xixiao Song, Yan Wang, Xia Li, Shanshan Jia, and Zhijing Wang Department of Neurology, Xi’an Children’s Hospital, Xi’an, Shaanxi 710003, China Correspondence should be addressed to Dong Wang; [email protected] Received 11 December 2013; Accepted 29 January 2014; Published 12 May 2014 Academic Editors: J. T. Efird, M. Godfrey, and W. Hall Copyright © 2014 Dong Wang et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Purpose. Epilepsy is a common chronic neurological disorder. We aim to investigate the underlying mechanism of epilepsy with partial least squares- (PLS-) based gene expression analysis, which is more sensitive than routine variance/regression analysis. Methods. Two microarray data sets were downloaded from the Gene Expression Omnibus (GEO) database. PLS analysis was used to identify differentially expressed genes. Gene ontology and network analysis were also implemented. Results. A total of 752 genes were identified to be differentially expressed, including 575 depressed and 177 overexpressed genes in patients. For GO enrichment analysis, except for processes related to the nervous system, we also identified overrepresentation of dysregulated genes in angiogenesis. Network analysis revealed two hub genes, CUL3 and EP300, which may serve as potential targets in further therapeutic studies. Conclusion. Our results here may provide new understanding for the underlying mechanisms of epilepsy pathogenesis and will offer potential targets for producing new treatments. 1. Introduction Epilepsy is a common chronic neurological disorder, which has devastating effects on patients and their families. ere are about 50 million epilepsy patients worldwide and the occurrence in developing countries is more than twice that in developed countries [1]. Currently there are more than 20 antiepileptic drugs available for epilepsy patients [2]; however, multidirectional interactions between seizures and the medications are still challenging for treating patients [3]. Exploring the biological alterations of patients may provide insights into the pathology and new targets for treatments. Large-scale microarray expression strategy has provided greater ease for investigating the underlying mechanisms of epilepsy. Several gene expression profiling studies have been carried out earlier and most of them used the routine variance/regression analysis [46]. However, this procedure cannot remove unaccounted array specific factors, such as certain demographic profiles. Compared with the routine analysis, previous studies [7, 8] proposed that partial least squares- (PLS-) based analysis is more robust in proceeding gene expression profile data with higher sensitivity. erefore, using PLS analysis may provide new understanding of the pathogenesis of epilepsy. In the current study, to identify truly differentially expressed genes between epilepsy patients and normal con- trols, we carried out a PLS analysis with two combined data sets from the Gene Expression Omnibus (GEO) database. Gene ontology (GO) enrichment analysis was also carried out for the selected genes to capture the biological relevant signatures. A network constructed by proteins encoded by dysregulated genes was used to identify key molecules among the differentially expressed genes. Our results here may provide new understanding on the pathogenesis of epilepsy. 2. Materials and Methods 2.1. Microarray Data. Two data sets (GSE4290 and GSE50161) from the GEO (http://www.ncbi.nlm.nih.gov/ geo/) database, which include 23 epilepsy patients and 13 healthy controls, were used in this study. Hindawi Publishing Corporation e Scientific World Journal Volume 2014, Article ID 731091, 5 pages http://dx.doi.org/10.1155/2014/731091

Upload: others

Post on 19-Oct-2020

7 views

Category:

Documents


0 download

TRANSCRIPT

  • Research ArticleGene Expression Profile Analysis in Epilepsy byUsing the Partial Least Squares Method

    Dong Wang, Xixiao Song, Yan Wang, Xia Li, Shanshan Jia, and Zhijing Wang

    Department of Neurology, Xi’an Children’s Hospital, Xi’an, Shaanxi 710003, China

    Correspondence should be addressed to Dong Wang; [email protected]

    Received 11 December 2013; Accepted 29 January 2014; Published 12 May 2014

    Academic Editors: J. T. Efird, M. Godfrey, and W. Hall

    Copyright © 2014 Dong Wang et al. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Purpose. Epilepsy is a common chronic neurological disorder. We aim to investigate the underlying mechanism of epilepsy withpartial least squares- (PLS-) based gene expression analysis, which is more sensitive than routine variance/regression analysis.Methods. Two microarray data sets were downloaded from the Gene Expression Omnibus (GEO) database. PLS analysis wasused to identify differentially expressed genes. Gene ontology and network analysis were also implemented. Results. A total of752 genes were identified to be differentially expressed, including 575 depressed and 177 overexpressed genes in patients. For GOenrichment analysis, except for processes related to the nervous system, we also identified overrepresentation of dysregulated genesin angiogenesis. Network analysis revealed two hub genes, CUL3 and EP300, which may serve as potential targets in furthertherapeutic studies. Conclusion. Our results here may provide new understanding for the underlying mechanisms of epilepsypathogenesis and will offer potential targets for producing new treatments.

    1. Introduction

    Epilepsy is a common chronic neurological disorder, whichhas devastating effects on patients and their families. Thereare about 50 million epilepsy patients worldwide and theoccurrence in developing countries is more than twice thatin developed countries [1]. Currently there are more than20 antiepileptic drugs available for epilepsy patients [2];however, multidirectional interactions between seizures andthe medications are still challenging for treating patients [3].Exploring the biological alterations of patients may provideinsights into the pathology and new targets for treatments.

    Large-scale microarray expression strategy has providedgreater ease for investigating the underlying mechanismsof epilepsy. Several gene expression profiling studies havebeen carried out earlier and most of them used the routinevariance/regression analysis [4–6]. However, this procedurecannot remove unaccounted array specific factors, such ascertain demographic profiles. Compared with the routineanalysis, previous studies [7, 8] proposed that partial leastsquares- (PLS-) based analysis is more robust in proceeding

    gene expression profile datawith higher sensitivity.Therefore,using PLS analysis may provide new understanding of thepathogenesis of epilepsy.

    In the current study, to identify truly differentiallyexpressed genes between epilepsy patients and normal con-trols, we carried out a PLS analysis with two combined datasets from the Gene Expression Omnibus (GEO) database.Gene ontology (GO) enrichment analysis was also carriedout for the selected genes to capture the biological relevantsignatures. A network constructed by proteins encoded bydysregulated genes was used to identify keymolecules amongthe differentially expressed genes. Our results here mayprovide new understanding on the pathogenesis of epilepsy.

    2. Materials and Methods

    2.1. Microarray Data. Two data sets (GSE4290 andGSE50161) from the GEO (http://www.ncbi.nlm.nih.gov/geo/) database, which include 23 epilepsy patients and 13healthy controls, were used in this study.

    Hindawi Publishing Corporatione Scientific World JournalVolume 2014, Article ID 731091, 5 pageshttp://dx.doi.org/10.1155/2014/731091

  • 2 The Scientific World Journal

    Table 1: Characteristics of the expression profile used in this study.

    Accession ID DescriptionGSM97800 Brain tissue from epilepsy patientGSM97803 Brain tissue from epilepsy patientGSM97804 Brain tissue from epilepsy patientGSM97805 Brain tissue from epilepsy patientGSM97807 Brain tissue from epilepsy patientGSM97809 Brain tissue from epilepsy patientGSM97811 Brain tissue from epilepsy patientGSM97812 Brain tissue from epilepsy patientGSM97816 Brain tissue from epilepsy patientGSM97817 Brain tissue from epilepsy patientGSM97820 Brain tissue from epilepsy patientGSM97825 Brain tissue from epilepsy patientGSM97827 Brain tissue from epilepsy patientGSM97828 Brain tissue from epilepsy patientGSM97833 Brain tissue from epilepsy patientGSM97834 Brain tissue from epilepsy patientGSM97840 Brain tissue from epilepsy patientGSM97846 Brain tissue from epilepsy patientGSM97848 Brain tissue from epilepsy patientGSM97849 Brain tissue from epilepsy patientGSM97850 Brain tissue from epilepsy patientGSM97853 Brain tissue from epilepsy patientGSM97855 Brain tissue from epilepsy patientGSM1214936 Brain tissue from normal controlGSM1214937 Brain tissue from normal controlGSM1214938 Brain tissue from normal controlGSM1214939 Brain tissue from normal controlGSM1214940 Brain tissue from normal controlGSM1214941 Brain tissue from normal controlGSM1214942 Brain tissue from normal controlGSM1214943 Brain tissue from normal controlGSM1214944 Brain tissue from normal controlGSM1214945 Brain tissue from normal controlGSM1214946 Brain tissue from normal controlGSM1214947 Brain tissue from normal controlGSM1214948 Brain tissue from normal control

    The twodata setswere both based on theGPL570platformAffymetrix Human Genome U133 Plus 2.0 Array. Detailedinformation of the samples is listed in Table 1.

    2.2. Detection of Differentially Expressed Genes. Normaliza-tion of raw intensity values was carried out with robust mul-tiarray analysis (RMA) [9]. The resulting log2-transformedexpression values of all probes were used for further PLSanalysis [10, 11], which is a dimension reduction method formodeling without imposing strong assumptions, to estimatethe effects for each probe in epilepsy patients. Briefly, NIPALSalgorithm [12] was firstly used to obtain PLS latent variablesderived from the expression profile; variable importance onthe projection (VIP) [13] was then calculated to estimate

    the effect of the expressed probes on the disease status ofthe patients. Finally, the empirical distribution of PLS-basedVIP was obtained with a permutation procedure (𝑁 =10000 times) and false discovered rate (FDR) of each probewas calculated based on the empirical distribution. Probeswith FDR value less than 0.05 were selected as differentiallyexpressed genes in this study.

    2.3. Enrichment Analysis. Identified differentially expressedprobes were annotated by using the simple omnibus formatin text (SOFT) format files. All genes were then mapped totheGeneOntology database [14], which provides a controlledvocabulary of terms for describing gene product charac-teristics. Hyper geometric distribution test was carried outto identify GO items enriched with differentially expressedgenes.

    2.4. Network Analysis. Most proteins function through inter-actions with other proteins. Proteins with more inter-actions with other proteins are supposed to play moreimportant roles in biological processes. To identify keymolecules among the differentially expressed genes, we con-structed an interaction network with the proteins encodedby selected genes by using the software Cytoscape (V2.8.3, http://www.cytoscape.org/) [15]. Interaction informa-tion of the proteins was obtained from the NCBI database(http://ftp.ncbi.nlm.nih.gov/gene/GeneRIF/). The number oflinks (interactions) for each protein was defined as its degree.Proteins with degrees more than 10 were selected as hubmolecules in this study.

    3. Results

    After quality control, two samples (GSM1214938 andGSM1214939) were excluded from subsequent analysis dueto aberrant RNA degradation. Thus, 23 epilepsy patientsand 11 healthy controls were used in PLS analysis. Sampleclassification according to the three selected latent variablesis illustrated in Figure 1. After FDR control, a total of752 genes were identified to be differentially expressed,including 575 depressed and 177 overexpressed genes inpatients. The top ten GO items enriched with differentiallyexpressed genes are listed in Table 2. Most of them (60%)are related to the nervous system, including nervoussystem development (GO:0007399), central nervous systemmyelin maintenance (GO:0007399), neuroligin clustering(GO:0007399), synapse assembly (GO:0007416), spinal cordmotor neuron differentiation (GO:0021522), and glial celldevelopment (GO:0021782).

    Figure 2 represents the interaction network of proteinsencoded by selected genes. Two proteins, CUL3 and EP300,were identified to be hub molecules, with degrees of 56 and21, respectively.

    4. Discussion

    Pathophysiology of epilepsy is highly complex. Gene expres-sion profiling is useful in investigating the underlying mech-anism of epilepsy. For the data analysis, creating a suitable

  • The Scientific World Journal 3

    Table 2: The top 10 GO items enriched with differentially expressed genes.

    GO id GO description GO class 𝑃 valueGO:0007155 Cell adhesion Process 3.74𝐸 − 05GO:0072659 Protein localization to plasma membrane Process 4.75𝐸 − 05GO:0001525 Angiogenesis Process 2.64𝐸 − 04GO:0007399 Nervous system development Process 9.26𝐸 − 04GO:0032286 Central nervous system myelin maintenance Process 1.43𝐸 − 03GO:0097118 Neuroligin clustering Process 1.43𝐸 − 03GO:0007416 Synapse assembly Process 1.59𝐸 − 03GO:0021522 Spinal cord motor neuron differentiation Process 2.57𝐸 − 03GO:0005509 Calcium ion binding Function 4.01𝐸 − 03GO:0021782 Glial cell development Process 4.18𝐸 − 03

    −0.2 −0.1 0 0.1 0.2 0.3 0.4 0.5 −0.50

    0.51

    −0.3−0.2−0.1

    00.10.20.30.40.50.6

    2nd PLS

    scores

    1st PLS scores

    3rd

    PLS

    scor

    es

    EpilepsyNormal

    Figure 1: Sample classification by using the three selected partialleast squares (PLS) latent variables.

    model to handle small sample sizes and large number ofgenes [7] remains challenging. Previous studies [7, 8] havedemonstrated better performance of the PLS-based methodthan common variance/regression analysis, which cannotremove hidden biological effects. Here we used PLS analysisto identify differentially expressed genes between epilepsypatients and healthy controls.

    As shown in Figure 1, the selected three latent variablesperformed well in classification of the samples. GO enrich-ment analysis of the selected genes revealed the overrep-resentation of differentially expressed genes in the nervoussystem.This is consistent with previous studies. For example,glial cells have been reported to play prominent roles inseizure precipitation and recurrence [16], and the glial celldevelopment was identified to be enriched with dysregulatedgenes in our study (𝑃 = 4.18×10−3). In addition, angiogenesis(GO:0001525) was also found to be overrepresented withdysregulated genes. Dysregulation of angiogenesis may berelated to the dysfunction of blood-brain barrier, contribut-ing to epileptogenesis [17]. Signs of angiogenesis were also

    reported to be corresponding with seizure-induced neuronaldeath in animal models of familial epilepsy [18]. Our resultshere further confirmed the involvement of angiogenesisprocess in the pathogenesis of epilepsy.

    According to the network analysis, CUL3 was identifiedto be a hub molecule with the highest degree (Figure 2).CUL3 is a core component and scaffold protein of an E3ubiquitin ligase complex. Previous expression studies havenot reported the differential expression of CUL3 in epilepsypatients. However, E3 ubiquitin ligase may affect the synapticfunctions in the central nervous system and the stability ofkainate receptors, which form a class of glutamate receptorsimplicated in epilepsy [19, 20]. Our results suggested thatCUL3 may serve as a potential target in therapeutic studies.

    EP300 is another hub gene with the degree of 21. Noreport of this gene and epilepsy has been proposed before.However, protein encoded by this gene is a transcriptionalcoactivator, which stimulates CREB-dependent gene expres-sion. Seizure disorder was reported to be more frequent inRubinstein-Taybi syndrome patients with CREBBP muta-tions [21]. In addition, the promoted signaling mechanismof EP300 is important in the neuronal survival process [22]and this gene was related to other neuronal disorders, suchas familial Alzheimer’s disease [22]. Thus, the correlation ofthis gene and epilepsy pathogenesis may involve the activityof CREB-dependent proteins and further investigation iswarranted.

    In summary, using two data sets from the GEO database,we carried out PLS-based gene expression analysis to inves-tigate the underlying pathology of epilepsy. Except for pro-cesses related to the nervous system, we also identifiedoverrepresentation of dysregulated genes in angiogenesis.Network analysis revealed two hub genes, CUL3 and EP300,which may serve as potential targets in further therapeuticstudies. Our results here may provide new understanding forthe underlyingmechanisms of epilepsy pathogenesis and willoffer potential targets for producing new treatments.

    Conflict of Interests

    The authors have no financial conflict of interests.

  • 4 The Scientific World Journal

    A1DACACCCNACNA NNVCCCANCAN33ANNNK3NK37A7RAAAB27AB2722ASASAAP2AP2FFDDDYSFDYSF3E3TTTLETLE3

    11CAAALBALB1 22CCCCL2CCL2K1OKHHHOOHOOH5HEXEXXPHXPHD7ADTHTHHSDHSDN3NCAAAPNAPN44SSSIX4SIX4C1CSNNNAPCNAPC8L8STTK38TK38

    2N2RHHHPNHPN2

    GGGGKIIITLGITLG 22BBBMPBMP2

    GGNNNOGNOG

    RGRGRGRGRARARARGRARG77PAPAPAK7PAK7

    595CCCDDC5CDC5

    XXATTTRXTRX

    6B6TNNNRC6NRC6

    SRSDDDARDARS

    RFFC5FC5FC54EH4HISTTHHH TTT1H4TT1H4T151KLHLHHL1HL1

    111SCCCAF1CAF1TTTEKTEK

    A2AEIIIF5AIF5A

    66INNNTS6NTS6

    RRRREPEPPORPORKKKITK

    2R2BMMMPR2MPR2 1A1MOOOB1OB166MMMAP6MAP6BBADBADBAD

    CS1CHMMMGCMGC

    C3CSNAAAPCAPC

    11BCCCCCCCNBCNB

    22CCCKS2CKS2

    P1PRAAALBPALBP

    73UUUSP3USP345G4GADDDD4DD4

    GIP1GGADDDD45GD45G

    111FOOOXOOXO

    AAAKKIIF1AKIF1A 1CDCCDC 1DH1DH1

    NNNNGMGMMNNNNNNM

    AR

    CCBBBOCBOC

    5555EEETV5ETV5

    11WWWIPI1WIPI1

    D2D2DDCITCITTEDTED

    0000EEEP300EP300

    131311KKKLF1KLF1

    L1LLLPLLLLLLAGLLAAAGLLLLAAA

    K2K2KKHHHIPKHIPK

    444SSSOX4SOX4 99MMMAP9MAP9

    AP4APDLLLLLGALGA

    JAJAAK1AK1

    AAAALIIIN7AIN7A

    11SSSBF1SBF1

    1111PDPDDDDPKDPK

    55PEEEA15EA15

    121KCCCNJ1CNJ1

    11DDDDDLG1DLG1

    11CCCCCRY1CRY1

    NNDDDSTNDSTN

    G2GCSNNNK1GNK1G

    DDPAPAAAALLDALLD

    1111PPPPPER1PER1

    55B55ITTTGBTGB

    DDTATAAF1DAF1D

    7070CCCEP7CEP7

    CCZXXXDCXDC

    101MYYYO1YO1

    1B1POOOLR1OLR1

    23232322MMMMMED2MED2F1FFFSRRRRREBFREBF

    44CCCCL4CCL4

    3333CCCCCCCL3CCL3

    P35PPPARHGGGAPGAP 6666BBBBBCL6BCL6

    NNNNPPPTENPTEN

    TRRRR TRETRET

    22PPPTK2PTK2

    B1BEPPPHBHPHB

    IIRS1IR

    I1IMMAAGIMAGI

    D9D9DDNEEEEEDDEDD

    22DDDIO2DIO2

    SSSKIS1WWWSBWSB

    11IIINING1NG1 00PHPHHHHF20HF20

    M2MTTTPMTPM

    141FKKKBP1KBP100SOSOSOOX10OX10

    3L3L1MEEED1ED1

    P3PFUUUBPUBP

    R1RRRRCORRCOR

    QQQQ IIQKIQKI

    282MMMED2MED2 TLTARRRNTRNT 1111SOSOOOOX1111O

    AAAARRRRRORARORA

    F2FFFPOPOOOOU3FU3FFFO

    484ZNZNNNNF14NF14

    ST1H4KH11ISHISHIIS

    PSPNPNPPPPEPPPEPP1H4DT1HISISIST1IST1

    65651TMETMEMETMEMEEEEEM1MEMEM1MMMMM11EEE1H4LLH1HHHISHIHIIHHHHHISIIIST1TST1STT1TSSTS 1HHISSI

    D2D2DDDDDDMTMTMTTHFDFDDH DDDDT

    4B4B44HIST2HISHIHIST22H4H2H4H442 T1H4CTHHHHHISTHISTDCUN1D5DDCUDD 555HHHHUN1UUN1UN1DDDDDDDPPDDCPPDDDSTSTSTTRBPDDDPPT D

    SSSSSSTSSSS 444TK4TTTSTK4SSS

    66USUUSUSP16SP16

    H4AHHHHIHIIHIHIIIIIIIST1HTST1HHHII

    88PPPPPHF8PHF8

    A2APCDPPPPPCPPP DDHADHDHA

    1CC1CC11C1111HISTHISTHISHISTSSSTSTTTTTT1H1HT1H1HT1T 11TTTT

    K1K1KKADADDDDRBKRBKKKD

    3333IILF3ILF3ILF3

    22BBBBBRD2B DDDBRD2B

    8888888SSSSS18S188S

    11YY1YYY1

    4AA4HISTSTTTT2H4T2T2H4TH44HHISSSSSSST4HST4H

    212122DDDDDDX2DDX2

    2222222OLOOLOLLIG2G22222LL HHHHHHEEE DDEEDEDEEDEE DD

    MMMCCMCCRPRPRPRPPPPP 1PS111PS111101MYYYH1YH1

    P1PSEEEEERBPERBP

    M1MICCICCCCCCAMCAM

    C9CDNNNNNAJCNNAJCN

    5A5A5AA555RPRRRPPS1551S 55P55TTTTTAF5TAF5

    111111EEEEERC1ERC111EE66TUTUUUBB6UBB6

    A1ASSSSSF3ASF3A

    F3F333FFTTTAFTAF

    R1RKKKRRKRRRRKRR

    S1SSS1SSSSNDNNDNDDDUFSUFFSDU SFSSDD

    AP3ATHTHHHHRAHRA

    4H4H4H444HISTT1H4444T

    GGPPPPPPIGPPIG

    IK

    121FBXF XXL2XL2

    C10C10CCCCZCCCCHCCCHC

    00SRRRSF10RSF10

    9999HDHDDDDAC9AC999D

    C3C3SSSSSMCSMC3

    1T11RURURUUNUUUNX1UNXUNX1U

    PT2PANNNGPNGP

    F8FMEEEGFEGF

    B4BCACCCNBCNB

    B1B1BBLAAAMBAMB

    A1AACACCACAACACCACNACNA

    M4MSRRRRMRRMG1GOOOLIGOLIG

    K5K5PCCCSKCSK5

    N4N4PTTTPNTPN77INNNTS7NTS7

    AARPPPL35APL35ACUL3

    242KLLHLHL2LHL2 D3DFXFXXXXYDXYD

    888888888COCOOOOPS8PS8S888888O

    KKPDPDDDDXKDXKD

    RSRTOPPPORPOR

    5050NUNNUUUUP5UP5MR99MMMMTMMTMMTM

    4F444HISTTT1T1H41HT1H411H4J1HIHHIIST1ST1I

    22222222CCDCDCDC DDDDC22DC22DCDC222DDDD6DKBTTTBDTBD

    44MXMXXD4MXD4

    1111SRSRRRRPK1RPK1

    H4I4HHHHISTHIHHISTHHH TTT1HT11111T111H11HHTTTUUUSTUSUSTK22KSSSRPKSRPK00ZBTTTB10TB10

    HHAAASPHPSPPASPHBBHIST1IH 11H4B1H1H4B1

    22SHMHMMT2MMT2A66APCCCDCDDHADDHAD

    A2AAADADDDDRADRA

    OM3OSHRRROOROO

    53NUNNUUUUP3UUP3U

    L1LNNNNNUPNUPL

    Figure 2: Interaction network constructedwith proteins encoded by selected genes. Proteinswithmore links are shown in bigger size. Proteinsshown in red are encoded by overexpressed genes in patients while those in blue are encoded by depressed genes in patients.

  • The Scientific World Journal 5

    Acknowledgment

    This study is supported by the Science and TechnologyPlanning Project of Xi’an, Shaanxi, China (YF07152).

    References

    [1] C. R. Newton andH. H. Garcia, “Epilepsy in poor regions of theworld,”The Lancet, vol. 380, no. 9848, pp. 1193–1201, 2012.

    [2] E. Perucca and T. Tomson, “The pharmacological treatment ofepilepsy in adults,”The Lancet Neurology, vol. 10, no. 5, pp. 446–456, 2011.

    [3] C. L. Harden and P. B. Pennell, “Neuroendocrine considerationsin the treatment of men and women with epilepsy,” The LancetNeurology, vol. 12, no. 1, pp. 72–83, 2013.

    [4] J. Lachos, M. Zattoni, H. G. Wieser et al., “Characterization ofthe gene expression profile of human hippocampus in mesialtemporal lobe epilepsy with hippocampal sclerosis,” EpilepsyResearch and Treatment, vol. 2011, Article ID 758407, 11 pages,2011.

    [5] S.-K. Kim, K.-C. Wang, S. J. Hong et al., “Gene expressionprofile analyses of cortical dysplasia by cDNA arrays,” EpilepsyResearch, vol. 56, no. 2-3, pp. 175–183, 2003.

    [6] Y. Tang, T. A. Glauser, D. L. Gilbert et al., “Valproic acid bloodgenomic expression patterns in children with epilepsy—a pilotstudy,” Acta Neurologica Scandinavica, vol. 109, no. 3, pp. 159–168, 2004.

    [7] T. R. Golub, D. K. Slonim, P. Tamayo et al., “Molecularclassification of cancer: class discovery and class prediction bygene expressionmonitoring,” Science, vol. 286, no. 5439, pp. 531–537, 1999.

    [8] S. Chakraborty, S. Datta, and S. Datta, “Surrogate variable anal-ysis using partial least squares (SVA-PLS) in gene expressionstudies,” Bioinformatics, vol. 28, no. 6, pp. 799–806, 2012.

    [9] R.A. Irizarry, B.Hobbs, F. Collin et al., “Exploration, normaliza-tion, and summaries of high density oligonucleotide array probelevel data,” Biostatistics, vol. 4, no. 2, pp. 249–264, 2003.

    [10] I. S. Helland, “On the structure of partial least squares regres-sion,” Communications in Statistics, vol. 17, no. 2, pp. 581–607,1988.

    [11] I. S. Helland, “Partial least squares regression and statisticalmodels,” Scandinavian Journal of Statistics, vol. 17, no. 2, pp. 97–114, 1990.

    [12] J. P. A. Martins, R. F. Teófilo, and M. M. C. Ferreira, “Computa-tional performance and cross-validation error precision of fivePLS algorithms using designed and real data sets,” Journal ofChemometrics, vol. 24, no. 6, pp. 320–332, 2010.

    [13] R. Gosselin, D. Rodrigue, and C. Duchesne, “A Bootstrap-VIPapproach for selecting wavelength intervals in spectral imagingapplications,” Chemometrics and Intelligent Laboratory Systems,vol. 100, no. 1, pp. 12–21, 2010.

    [14] M. Ashburner, A. Ball, J. A. Blake et al., “Gene ontology: toolfor the unification of biology. The gene ontology consortium,”Nature Genetics, vol. 25, no. 1, pp. 25–29, 2000.

    [15] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a softwareenvironment for integrated models of biomolecular interactionnetworks,” Genome Research, vol. 13, no. 11, pp. 2498–2504,2003.

    [16] A. Vezzani, E. Aronica, A. Mazarati et al., “Epilepsy and braininflammation,” Experimental Neurology, vol. 244, pp. 11–21,2013.

    [17] M. Morin-Brureau, V. Rigau, and M. Lerner-Natoli, “Why andhow to target angiogenesis in focal epilepsies,” Epilepsia, vol. 53,supplement 6, pp. 64–68, 2012.

    [18] M. Sakurai, T. Morita, T. Takeuchi et al., “Relationship of angio-genesis and microglial activation to seizure-induced neuronaldeath in the cerebral cortex of Shetland Sheepdogs with familialepilepsy,” American Journal of Veterinary Research, vol. 74, no.5, pp. 763–770, 2013.

    [19] J. Marshall, L. A. C. Blair, and J. D. Singer, “BTB-kelch proteinsand ubiquitination of kainate receptors,” Advances in Experi-mental Medicine and Biology, vol. 717, pp. 115–125, 2011.

    [20] G.D. Salinas, L. A. C. Blair, L. A.Needleman et al., “Actinfilin is aCul3 substrate adaptor, linking GluR6 kainate receptor subunitsto the ubiquitin-proteasome pathway,”The Journal of BiologicalChemistry, vol. 281, no. 52, pp. 40164–40173, 2006.

    [21] E. K. Schorry, M. Keddache, N. Lanphear et al., “Genotype-phenotype correlations in Rubinstein-Taybi syndrome,” Ameri-can Journal of Medical Genetics A, vol. 146, no. 19, pp. 2512–2519,2008.

    [22] K. Yukawa, T. Tanaka, S. Tsuji, and S. Akira, “Regulation oftranscription factor C/ATF by the cAMP signal activation inhippocampal neurons, and molecular interaction of C/ATFwith signal integratorCBP/p300,”Molecular BrainResearch, vol.69, no. 1, pp. 124–134, 1999.

  • Submit your manuscripts athttp://www.hindawi.com

    Stem CellsInternational

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    MEDIATORSINFLAMMATION

    of

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Behavioural Neurology

    EndocrinologyInternational Journal of

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Disease Markers

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    BioMed Research International

    OncologyJournal of

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Oxidative Medicine and Cellular Longevity

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    PPAR Research

    The Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014

    Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Journal of

    ObesityJournal of

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Computational and Mathematical Methods in Medicine

    OphthalmologyJournal of

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Diabetes ResearchJournal of

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Research and TreatmentAIDS

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Gastroenterology Research and Practice

    Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

    Parkinson’s Disease

    Evidence-Based Complementary and Alternative Medicine

    Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com